Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Jul 12–Jul 19, 2026)
Here’s what’s on the biotech calendar for July 12–July 19: 1 FDA decision dates, 3 trial catalysts, and 0 earnings reports from tracked companies.
💊 FDA Decisions (PDUFA Dates)
| Date | Ticker | Drug | Indication | Type |
|---|---|---|---|---|
| 2026-07-17 | CELC | — | a significant number of patients with HR+/HER2- advanced bre | NDA |
🧪 Trial Catalysts & Milestones
- OSTX — 2026-07-15: Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patie
- OSTX — 2026-07-16: Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
- OSTX — 2026-07-17: Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Se
📡 Run-up Radar Highlights
Stocks entering the pre-catalyst window with the strongest setups (full radar is a Premium feature):
- CADL — Phase 2 — Recruiting in 20 days, score 60/100
- IBRX — Phase 2 — Recruiting in 19 days, score 55/100
- CELC — NDA in 5 days, score 55/100
📈 Last Week’s Biggest Gainers
- CRNX +98.74% (volume 62.2x average)
- LASR +27.32% (volume 3.2x average)
- PLBL +26.48% (volume 11.3x average)
- PENG +25.13% (volume 4.4x average)
- DSC +21.38% (volume 0.7x average)
Track your tickers on the BioRadar dashboard →
This digest is for informational purposes only and is not investment advice. Always do your own research.